普雷迪尼索隆20毫克与40毫克在复杂的区域性疼痛综合征I型:一个随机对照试验
Jayantee Kalita1, Prakash C Pandey1, Ruchi Shukla1
1Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh 226014, India.
概括
普雷迪尼索隆20毫克在治疗复杂区域性疼痛综合征I型 (CRPS-I) 中与40毫克一样有效. 这种较低的剂量也证明了糖尿病患者的睡眠质量和安全性得到改善.
科学领域:
- 疼痛管理 疼痛管理
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质类固醇因其在治疗复杂区域性疼痛综合征I型 (CRPS-I) 的有效性而闻名.
- 对于CRPS-I,皮质类固醇的最佳剂量仍然是一个研究领域.
研究的目的:
- 在CRPS-I患者中比较两种不同剂量的普雷迪尼索隆 (20mg vs. 40mg) 的疗效和安全性.
- 评估这些剂量对疼痛,功能状态和睡眠质量的影响.
主要方法:
- 这是一项开放的随机对照试验,涉及50名肩部CRPS-I患者,CRPS得分≥8.8.
- 患者每天接受40毫克 (I组) 或20毫克 (II组) 的普雷迪尼索隆,持续14天,然后逐渐减少.
- 结果包括疼痛视觉模拟量表 (VAS) 的降低,CRPS得分和每日睡眠干扰量表 (DSIS),以及对不良事件的监测.
主要成果:
- 一个月后,所有患者的VAS得分都降低了50%以上,两组之间没有显著差异.
- 睡眠质量 (DSIS) 在20毫克组显著改善 (p=0.04).
- 接受40毫克的患者需要更频繁地调整抗糖尿病药物 (p=0.04),这表明糖尿病患者的潜在安全问题.
结论:
- 普雷迪尼索隆20毫克在治疗CRPS-I时不低于40毫克.
- 20毫克的剂量提供了可比的疼痛缓解,改善了睡眠质量和更好的安全性,特别是对于糖尿病患者.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
01:25Analgesia and Pain Management
673
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
673
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.4K